 BUFFALO, N.Y., May 17, 2021 GLOBE NEWSWIRE -- Athenex, Inc. NASDAQ: ATNX, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that investigators from Texas Childrens Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine presented new clinical data from the ongoing GINAKIT2 phase 1 study of Athenexs cell therapy candidate KUR-501 targeting GD2 in neuroblastoma at the American Society of Gene Cell Therapy ASGCT 24 th Annual Meeting on Friday, May 14, at 11 am ET. 